General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Aligos Therapeutics in Pricing of US$83.6 Million Public Offering

July 1, 2021
Bay Area team represents the clinical-stage biopharmaceutical company in the offering.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of US$19 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock at the same terms and conditions. All of the shares of common stock are being offered by Aligos. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately US$83.6 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on July 6, 2021, subject to customary closing conditions.

Latham & Watkins LLP represents Aligos Therapeutics in the offering with a corporate deal team led by Bay Area partners Mark Roeder and John Williams, with associates Theresa Bloom, Christopher Pham, and Natalie Robertson. Advice has also been provided on employee benefits and compensation matters by Bay Are partner Jay Metz and associate Erik Ward; on tax matters by Bay Area partner Kirt Switzer and associate Gregory Conyers; on regulatory matters by Washington, D.C. partner John Manthei, Bay Area counsels Betty Pang and Heather Deixler, and associates Monica Groat in Washington, D.C., Ning Heather Lui in Los Angeles, Kiera Murphy in San Diego, and Lee Staley in Boston; and on data and technology matters by New York partner Alan Tamarelli, Bay Area partner Christopher Hazuka, and Boston associate Seth Appiah-Opoku.